Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H2 2018’, provides in depth analysis on Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Oncology, Ophthalmology, Immunology, Cardiovascular, Gastrointestinal, Infectious Disease and Respiratory under development targeting Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)

- The report reviews Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Avipero Ltd

Bausch Health Companies Inc

Pliant Therapeutics Inc

Strykagen Corp

Tasly Pharmaceutical Group Co Ltd

Avipero Ltd

Bausch Health Companies Inc

Pliant Therapeutics Inc

Strykagen Corp

Tasly Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Overview

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Companies Involved in Therapeutics Development

Avipero Ltd

Bausch Health Companies Inc

Pliant Therapeutics Inc

Strykagen Corp

Tasly Pharmaceutical Group Co Ltd

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Drug Profiles

7HP-349 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody + Small Molecule - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AXR-159 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AXT-108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-16Y - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Antagonize Integrin Alpha V Beta 3 and Integrin Alpha 5 Beta 1 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOD-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLN-74809 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ITGAV and ITGB1 for Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-234 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-425 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-516s - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-969 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stryka-978 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

StrykaPro-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Antagonize Alpha5Beta1 Integrin for Breast and Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Dormant Products

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Discontinued Products

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Product Development Milestones

Featured News & Press Releases

Aug 06, 2018: Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

Jul 24, 2018: 7 Hills Pharma appoints Lionel D. Lewis as chief medical officer

Jun 26, 2018: 7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program

Jun 19, 2018: 7 Hills Pharma Launches With $2 Million SBIR Grant in Addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance

Dec 23, 2013: Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis

Oct 25, 2013: Santarus Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting

Mar 10, 2011: Santarus Initiates Phase I Clinical Study With SAN-300

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Avipero Ltd, H2 2018

Pipeline by Bausch Health Companies Inc, H2 2018

Pipeline by Pliant Therapeutics Inc, H2 2018

Pipeline by Strykagen Corp, H2 2018

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports